MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.395
-0.005 (-0.36%)
At close: Nov 13, 2026, 4:00 PM EST
1.390
-0.005 (-0.36%)
After-hours: Nov 13, 2026, 4:15 PM EST
MediciNova Employees
MediciNova had 6 employees as of December 31, 2025. The number of employees decreased by 7 or 53.85% compared to the previous year. That makes MediciNova the 41,495th largest employer in the world and 6,371st in the United States.
Employees
6
Change (1Y)
-7
Growth (1Y)
-53.85%
Revenue / Employee
$155,953
Profits / Employee
-$1,757,606
Market Cap
68.66M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 6 | -7 | -53.85% |
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | 0 | - |
| Dec 31, 2022 | 13 | 2 | 18.18% |
| Dec 31, 2021 | 11 | 2 | 22.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 214 |
| Gossamer Bio | 162 |
| Heron Therapeutics | 128 |
| Fortress Biotech | 78 |
| Acrivon Therapeutics | 76 |
| Verrica Pharmaceuticals | 76 |
| PDS Biotechnology | 21 |
| Cingulate | 14 |
MNOV News
- 1 day ago - MediciNova Quarterly report: Q3 2026 - Filings
- 4 weeks ago - MediciNova CEO provides update on results from Phase 2 trial of MN-001 - TheFly
- 5 weeks ago - MediciNova to Participate in the Maxim Growth Summit - GlobeNewsWire
- 6 weeks ago - MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001 - TheFly
- 6 weeks ago - MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) - GlobeNewsWire
- 7 weeks ago - MediciNova completes LPLV in Phase 2b/3 clinical trial evaluating MN-166 - TheFly
- 7 weeks ago - MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) - GlobeNewsWire
- 1 month ago - MediciNova initiated with a Buy at Roth Capital - TheFly